Form 4: Kathleen Tregoning, Director at Spero Therapeutics, Acquires 20,000 Shares of Common Stock

Director Kathleen Tregoning acquired 20,000 shares of Spero Therapeutics common stock on May 29, 2024, in the form of restricted stock units.

Summary

• Kathleen Tregoning, a director at Spero Therapeutics, acquired 20,000 shares of common stock on May 29, 2024.
• The acquisition was in the form of restricted stock units (RSUs).
• Each RSU represents the right to receive one share of common stock upon vesting.
• The RSUs vest on May 29, 2025, contingent upon Tregoning's continued service with the company.
• Following the transaction, Tregoning beneficially owns 55,000 shares of Spero Therapeutics common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports a standard insider transaction. The acquisition of shares by a director is generally viewed as a positive sign, but it's a routine event.

Positives

• The acquisition of shares by a director can be seen as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders and their holdings in the company's stock.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it indicates confidence from a company director.

Key Dates